This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Dermatology Times
OCTOBER 3, 2023
These insights highlight the crucial role of systemic therapies in the comprehensive management of moderate to severe atopic dermatitis.
74 
Dermatology Times
NOVEMBER 20, 2024
aureus in atopic dermatitis. ENS-002 targets S.
73 This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dermatology Times
JUNE 2, 2024
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
77 
Dermatology Times
OCTOBER 5, 2023
Colleen Cotton, MD, discusses the treatment landscape of pediatric atopic dermatitis, highlights from her session at Maui Derm NP+PA in Asheville, NC, and more.
74 
Dermatology Times
SEPTEMBER 18, 2024
From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.
41 
Dermatology Times
APRIL 11, 2024
In one study, researchers were unable to detect any changes in the gut microbiome of patients treated with tapering dose of steroids or a probiotic mixture.
81 
Dermatology Times
MARCH 4, 2024
Test your knowledge on the AAD's recommendations for phototherapy, monoclonal antibodies, JAK inhibitors, and systemic therapies in the latest guidelines.
73 
First Derm
FEBRUARY 21, 2024
Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?
59 
First Derm
JUNE 10, 2024
Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.
45 
Dermatology Times
FEBRUARY 17, 2024
Investigators revealed the development of a non-invasive molecular test utilizing gene expression differences in skin diseases such as atopic dermatitis, psoriasis, and mycosis fungoides, with the potential to accurately diagnose and identify super-responders to targeted systemic therapies.
87 
Dermatology Times
OCTOBER 27, 2024
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
53 
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance. The study appears in Dermatitis.
77 
Dermatology Times
JANUARY 8, 2024
The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.
80 
Dermatology Times
AUGUST 27, 2024
The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.
45 
Dermatology Times
DECEMBER 12, 2023
At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."
74 
The Dermatology Digest
DECEMBER 11, 2024
Currently, there arent a lot of good therapies that target mast cells, so we think that our approach could potentially have huge benefits in many skin conditions, including rosacea, eczema, urticaria and mastocytosis. There are no good therapies for flushing, so this is a significant unmet need.
41 
Dermatology Times
DECEMBER 7, 2023
A patient returns to your clinic seeking systemic therapy for her AD while postpartum and breastfeeding. Test your knowledge on injectables.
73 
Dermatology Times
DECEMBER 10, 2024
Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.
36 
Dermatology Times
OCTOBER 3, 2023
As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.
74 
Dermatology Times
DECEMBER 22, 2023
The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.
74 
Dermatology Times
DECEMBER 11, 2023
From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.
73 
Dermatology Times
JUNE 2, 2024
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
52 
Dermatology Times
MAY 30, 2024
Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)
72 
Dermatology Times
DECEMBER 4, 2024
Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.
36 
Dermatology Times
AUGUST 9, 2024
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
41 
Dermatology Times
NOVEMBER 3, 2023
Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.
74 Dermatology Times
JULY 13, 2024
A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.
57 
The Dermatology Digest
MARCH 7, 2024
More Conference Coverage Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now SOCS Turns 20!
74 
The Dermatology Digest
FEBRUARY 26, 2024
2 In this review, we highlight the “epithelial barrier hypothesis” proposed by Akdis, discuss the important roles of the skin, gut, and respiratory barriers, and discuss novel therapies. Impairment in tight junction expression has been shown to contribute to the barrier dysfunction observed in patients with atopic dermatitis.
74 
Dermatology Times
MARCH 29, 2024
Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.
36 
The Dermatology Digest
MARCH 7, 2024
Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Just because they are little doesn’t mean we should be afraid to treat them and make their skin disease better,” she stresses. Watch Now SOCS Turns 20!
68 
The Dermatology Digest
FEBRUARY 14, 2024
Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.
78 
The Dermatology Digest
MARCH 7, 2024
More Conference Coverage Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now SOCS Turns 20!
69 
Dermatology Times
SEPTEMBER 20, 2023
Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.
41 
First Derm
DECEMBER 4, 2023
Dry skin is a very common problem in people with atopic dermatitis, a chronic inflammatory skin condition characterized by patches of itchy, dry, red, and inflamed skin. Atopic dermatitis (eczema) characterized by itchy patches of red, inflamed, dry skin. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis.
92 
US Dermatologt Partners
NOVEMBER 25, 2023
Atopic dermatitis (AD) is a multifaceted condition that can significantly impact a patient’s quality of life. I think that dermatitis started showing up once my psoriasis started showing up,” Dean said. “It As a physician, I have to do a better job intervening here [and] switch our systemic therapies.”
36 
The Dermatology Digest
FEBRUARY 8, 2024
This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We And the Skin Disease of the Year Is….
78 
Dermatology Times
OCTOBER 28, 2024
Posters at AMCP Nexus analyzed the burden of flares on patients with atopic dermatitis (AD) and the impact initiating ruxolitinib cream had on use of other therapies.
36 
Dermatology Times
JUNE 20, 2024
Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation (..)
36 
US Dermatologt Partners
AUGUST 23, 2023
Atopic Dermatitis, more commonly known as eczema, is a common skin condition impacting one in 10 Americans. In this blog, Dr. Ackerman walks through just what atopic dermatitis is, how dermatologists help, available medications an treatments, and at-home care steps. Millions of people in the U.S.
36 
First Derm
MARCH 22, 2024
Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Who’s at Risk : Affects both genders and all ages, but more common in infants and children with atopic dermatitis.
52 
The Dermatology Digest
JANUARY 29, 2024
From new topical therapies and novel biologics including nemolizumab and lebrikizumab to OX40 and OX40 ligand monoclonal antibodies, the atopic dermatitis pipeline is full, says Andrew Blauvelt, MD, MBA, an Investigator at Oregon Medical Research Center in Portland. appeared first on The Dermatology Digest.
28 
First Derm
JUNE 23, 2024
1] Three main categories of eczema are atopic eczema, contact dermatitis and stasis dermatitis. To prevent that your dermatologist will advice you to slowly taper off the topical steroid, shift from high to mild potency ones, or every other day therapy. The American Contact Dermatitis Society recognizes it as an allergen.
59 
Dermatology Times
DECEMBER 3, 2024
Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.
41
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content